Skip to content

Clinical trials

Hemophilia A trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hemophilia A Country / region: United States Clear all

270 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20014
20024
20032
20042
20059
20068
20072
20084
20098
201012
201112
201213
20139
201415
201518
201612
201718
201825
20198
202016
202111
202211
202314
202411
20256
202610

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed168
Terminated31
Recruiting30
Active, not recruiting15
Withdrawn10
Unknown status10
Not yet recruiting3
Enrolling by invitation2
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S28
Baxalta now part of Shire27
Bayer23
Pfizer15
Hoffmann-La Roche12
Octapharma9
American Thrombosis and Hemostasis Network7
Bioverativ Therapeutics Inc.7
Sanofi7
BioMarin Pharmaceutical6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hemophilia A270
Hemophilia B53
Hematologic Diseases19
Blood Coagulation Disorders17
Hemostatic Disorders15
Coagulation Protein Disorders13
Hemorrhagic Disorders13
Blood Coagulation Disorders, Inherited11
Genetic Diseases, Inborn11
Hemorrhage11

Trials

Showing 1 to 25 of 270. Each trial links to its page on Pharma Observatory.

170 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.